NCT01967823 2021-03-24T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing CancerNational Institutes of Health Clinical Center (CC)Phase 2 Completed11 enrolled 12 charts